All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...

Also: Deeper looks at Microsoft, Tesla (and Musk) and ways to broaden your investment horizons and lower your risk.

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...